FINWIRES · TerminalLIVE
FINWIRES

Leerink Partners Downgrades Gilead Sciences to Market Perform From Outperform, Adjusts PT to $127 From $146

By

Gilead Sciences (GILD) has an average rating of overweight and mean price target of $159.74, according to analysts polled by FactSet.

What else is happening in Research?